Biohaven Ltd.
For the period ended Mar 31, 2026. Filed May 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 4, 2026
BHVN$15.11-0.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(Amounts in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(130,532) | $(221,677) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 2,366 | 2,246 |
| Non-cash share-based compensation | 28,286 | 53,062 |
| Issuance of common shares as payment under license and other agreements | 858 | 4,844 |
| Change in fair value of forward contract and derivative liabilities | — | 3,610 |
| Change in fair value of notes payable | 3,012 | — |
| Other non-cash items, net | (837) | (2,844) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current and non-current assets | 12,564 | (7,238) |
| Accounts payable | (1,221) | 91 |
| Accrued expenses and other current and non-current liabilities | (64,414) | 2,782 |
| Net cash used in operating activities | (149,918) | (165,124) |
| Cash flows from investing activities: | ||
| Proceeds from maturities of marketable securities | 35,000 | 210,000 |
| Purchases of marketable securities | (19,788) | (44,660) |
| Purchases of property and equipment | — | (461) |
| Net cash provided by investing activities | 15,212 | 164,879 |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common shares | 178,884 | — |
| Proceeds from issuance of common shares under 2022 Equity Incentive Plan | 132 | 369 |
| Other financing activities, net | — | — |
| Net cash provided by financing activities | 179,016 | 369 |
| Effects of exchange rates on cash, cash equivalents, and restricted cash | 16 | 23 |
| Net increase in cash, cash equivalents, and restricted cash | 44,326 | 147 |
| Cash, cash equivalents, and restricted cash at beginning of period | 232,779 | 102,542 |
| Cash, cash equivalents, and restricted cash at end of period | $277,105 | $102,689 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.